长寿和萨科佩尼亚的甲福尔明:衰老中的治疗悖论
Song-Yi Han1, Mukesh Kumar Yadav2, Jing-Hua Wang3
1College of Korean Medicine, Dongguk University, 32 Dongguk-ro, Goyang 10326, Gyeonggi-do, Republic of Korea.
Biomedicines
|February 27, 2026
概括
甲胺可能会保护脆弱个体的肌肉衰老,但在健康的老年人中阻碍肌肉衰老. 精确的老年药理学是平衡新陈代谢健康和肌肉功能的关键.
科学领域:
- 老年学和运动生理学
- 代谢和肌肉骨衰老的发生
背景情况:
- 甲福明是一种常见的抗糖尿病药物,通过改善新陈代谢,减少氧化应激和炎症,显示出对老年保护的潜力.
- 它对与年龄相关的肌肉损失 (肉类衰老) 的影响受到争论,从观察和干预研究中得到了相互矛盾的证据.
研究的目的:
- 为了调和甲胺对骨肌肉衰老和肉症的相互矛盾影响.
- 探索甲胺在老年人群中的治疗作用的上下文依赖性.
主要方法:
- 观察,流行病学和随机干预试验数据的审查和综合.
- 对甲胺的分子机制的分析,包括AMP激活蛋白激酶 (AMPK) 和哺乳动物目标拉巴素复合物1 (mTORC1) 信号通路.
主要成果:
- 观察性研究将甲福明与胰岛素抵抗性老年人中较低的肉症患病率联系在一起,这表明通过改善全身代谢来获得间接益处.
- 在健康的老年人中进行的干预试验表明,甲福明可以通过激活AMPK和抑制mtORC1.1,从而阻碍运动诱导的肌肉生长和蛋白质合成.
- 这些相反的结果突显出一种上下文依赖的治疗悖论.
结论:
- 甲福明可以为脆弱的,抗胰岛素的个体提供代谢益处,但可以限制身体活跃,健康的老年人中的合成代谢适应.
- 精确的老年药理学对于平衡新陈代谢长寿与肌肉骨健康的保持在衰老中至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Pharmacodynamics in Geriatric Patients: Effects of Age
284
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
284
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
299
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
299
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
324
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
324


